Solid Biosciences (SLDB) News Today

Solid Biosciences Inc. (NASDAQ:SLDB) shares have moved on the back of better-than-expected quarterly results, broker updates and revised earnings forecasts. Here’s what investors need to know:

• Positive Sentiment: Shares jumped nearly 10% after the company reported Q2 results that beat estimates by $0.09 per shareSolid Biosciences Shares Up 9.9% Following Better-Than-Expected Earnings
• Positive Sentiment: Solid Biosciences posted Q2 EPS of $(0.42), beating analyst expectations of $(0.51) by $0.09Solid Biosciences Posts Earnings Results, Beats Estimates By $0.09 EPS
• Positive Sentiment: Cantor Fitzgerald raised its FY2025 EPS estimate to $(1.86) from $(2.06) and maintained an Overweight rating with a $16.00 targetCantor Fitzgerald Raises FY2025 EPS Estimate
• Positive Sentiment: Wedbush increased its Q3 2025 EPS forecast to $(0.38) from $(0.46), reiterating an Outperform rating and $14.00 price targetWedbush Raises Q3 2025 EPS Forecast
• Positive Sentiment: Chardan Capital reaffirmed its Buy rating with a $15.00 target, citing significant upside potentialChardan Capital Reaffirms Buy Rating
• Neutral Sentiment: Leerink Partnrs projected Q1 2026 EPS of $(0.46) and reiterated a full‐year loss forecast of $(2.84) per shareLeerink Partnrs Issues Q1 2026 EPS Estimates for Solid Biosciences
• Negative Sentiment: Wedbush cut its overall price target on SLDB from $17.00 to $14.00 despite keeping an Outperform ratingWedbush Lowers Price Target to $14.00
• Negative Sentiment: JPMorgan Chase & Co. cut its price target to $13.00 from $15.00, although it kept an Overweight ratingJPMorgan Lowers SLDB Price Target to $13.00
• Negative Sentiment: HC Wainwright trimmed Q3 2025 EPS guidance to $(0.45) from $(0.43), while maintaining a Buy rating with a $20.00 objectiveHC Wainwright Cuts Q3 2025 EPS Estimate
• Negative Sentiment: HC Wainwright also lowered its FY2029 EPS forecast to $1.07 from $1.10, though keeping a Buy rating and $20.00 targetHC Wainwright Lowers FY2029 EPS Forecast